Literature DB >> 14667212

Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.

Jean Rivier1, Judit Erchegyi, Carl Hoeger, Charleen Miller, William Low, Sandra Wenger, Beatrice Waser, Jean-Claude Schaer, Jean Claude Reubi.   

Abstract

Hypothesizing that structural constraints in somatostatin (SRIF) analogues may result in receptor selectivity, and aiming to characterize the bioactive conformation of somatostatin at each of its five receptors, we carried out an N(beta)-methylated aminoglycine (Agl) scan of the octapeptide H-c[Cys(3)-Phe(6)-Phe(7)-dTrp(8)-Lys(9)-Thr(10)-Phe(11)-Cys(14)]-OH (SRIF numbering) (ODT-8) that is potent at all SRIF receptor subtypes (sst's) but sst(1). We found that H-c[Cys-LAgl(N(beta)Me,benzoyl)-Phe-DTrp-Lys-Thr-Phe-Cys]-OH (4), H-c[Cys-Phe-LAgl(N(beta)Me,benzoyl)-Trp-Lys-Thr-Phe-Cys]-OH (6), H-c[Cys-Phe-LAgl(N(beta)Me,benzoyl)-dTrp-Lys-Thr-Phe-Cys]-OH (8), and H-c[DCys-Phe-LAgl(N(beta)Me,benzoyl)-DTrp-Lys-Thr-Phe-Cys]-OH (10) had high affinity (IC(50) = 14.3, 5.4, 5.2, and 3.4 nM, respectively) and selectivity for sst(4) (>50-fold over the other receptors). The l-configuration at positions 7 and 8 (l(7), l(8)) yields greater sst(4) selectivity than the l(7), d(8) configuration (6 versus 8). Peptides with the d(7), l(8) (7) and d(7), d(8) (9) configurations are significantly less potent at all receptors. H-c[Cys-Phe-Phe-DTrp-LAgl(betaAla)-Thr-Phe-Cys]-OH (16), H-c[Cys-Phe-Phe-DTrp-DAgl(betaAla)-Thr-Phe-Cys]-OH (17), and their N(beta)Me derivatives at position 9 (18, 19) were essentially inactive. Potent but less sst(4)-selective were members of the Agl-scan at positions 10, H-c[Cys-Phe-Phe-dTrp-Lys-lAgl(N(beta)Me,HO-Ac)-Phe-Cys]-OH (20, IC(50) = 6.5 nM), and 11, H-c[Cys-Phe-Phe-DTrp-Lys-Thr-LAgl(N(beta)Me,benzoyl)-Cys]-OH (22, IC(50) = 6.9 nM), while the d-configuration at positions 10 (21) and 11 (23) led to reduced affinity. One of our best analogues, 8, is an agonist when tested for its ability to inhibit forskolin-stimulated cAMP accumulation in sst(4)-transfected CCL39 cells (EC(50) = 1.01 nM). All Agl-containing analogues were first synthesized using unresolved Fmoc-Agl(N(beta)Me,Boc)-OH, and the diastereomers were separated using HPLC. Chiral assignment at the Agl-containing residue was subsequently done using enzymatic degradation and by de novo synthesis in the cases of H-c[Cys-Phe-DAgl(N(beta)Me,benzoyl)-DTrp-Lys-Thr-Phe-Cys]-OH (9) and H-c[DCys-Phe-DAgl(N(beta)Me,benzoyl)-DTrp-Lys-Thr-Phe-Cys]-OH (11), starting with the papain-resolved Fmoc-DAgl(Boc). These results suggested that the orientation of side chains at position 6, 7, or 11 with respect to the side chains of residues 8 and 9 may be independently responsible for sst(4) selectivity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667212     DOI: 10.1021/jm030243c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Synthesis of protected norcysteines for SPPS compatible with Fmoc-strategy.

Authors:  Manoj P Samant; Jean E Rivier
Journal:  Tetrahedron Lett       Date:  2007-07-16       Impact factor: 2.415

2.  Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice.

Authors:  Agata Mulak; Muriel Larauche; Mandy Biraud; Mulugeta Million; Jean Rivier; Yvette Taché
Journal:  Peptides       Date:  2014-11-05       Impact factor: 3.750

3.  Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.

Authors:  Manoj P Samant; Richard White; Doley J Hong; Glenn Croston; P Michael Conn; Jo Ann Janovick; Jean Rivier
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

4.  Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR.

Authors:  Christy Rani R Grace; Judit Erchegyi; Steven C Koerber; Jean Claude Reubi; Jean Rivier; Roland Riek
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

5.  Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.

Authors:  Judit Erchegyi; Renzo Cescato; Christy Rani R Grace; Beatrice Waser; Véronique Piccand; Daniel Hoyer; Roland Riek; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

6.  Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity.

Authors:  Judit Erchegyi; Christy Rani R Grace; Manoj Samant; Renzo Cescato; Veronique Piccand; Roland Riek; Jean Claude Reubi; Jean E Rivier
Journal:  J Med Chem       Date:  2008-04-12       Impact factor: 7.446

7.  Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR.

Authors:  Christy Rani R Grace; Judit Erchegyi; Jean Claude Reubi; Jean E Rivier; Roland Riek
Journal:  Biopolymers       Date:  2008-12       Impact factor: 2.505

Review 8.  Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?

Authors:  Li-Chun Lin; Etienne Sibille
Journal:  Front Pharmacol       Date:  2013-09-09       Impact factor: 5.810

9.  Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain.

Authors:  Boglárka Kántás; Rita Börzsei; Éva Szőke; Péter Bánhegyi; Ádám Horváth; Ágnes Hunyady; Éva Borbély; Csaba Hetényi; Erika Pintér; Zsuzsanna Helyes
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.